| Date Filed | Type | Description |
| 08/25/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Company” or “Innoviva”) and you regarding the details of your employment with the Company. Your employment with the Company hereunder will commence on a date mutually agreeable to you and the Company, but in all events no later than August 21, 2023 (the date on which your employment commences being, the “Commencement Date",
"Innoviva Appoints Stephen Basso as Chief Financial Officer BURLINGAME, Calif., August 25, 2023 – Innoviva, Inc. , a diversified holding company with a portfolio of royalties and other healthcare assets, today announced the appointment of Stephen Basso as its Chief Financial Officer, effective August 21, 2023. “We are excited to welcome Stephen to our executive leadership team and believe the Company will benefit greatly from his background and experience,” said Pavel Raifeld, Chief Executive Officer of Innoviva. “I look forward to working with Stephen to advance our strategy and create shareholder value.” Mr. Basso brings more than 30 years of experience in the financial services industry and financial leadership in the pharmaceutical industry. Prior to joining Innoviva, Mr. Basso served a..." |
|
| 08/07/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/02/2023 |
4
| Koziel Margaret (Chief Medical Officer) has filed a Form 4 on Innoviva, Inc.|
Txns:
| Granted 60,000 options to buy
@ $13.55, valued at
$813k
|
|
| 08/02/2023 |
3
| Koziel Margaret (Chief Medical Officer) has filed a Form 3 on Innoviva, Inc. |
| 08/02/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/02/2023 |
8-K
| Quarterly results |
| 07/11/2023 |
SC 13D/A
| Innoviva, Inc. reports a 85.3% stake in ARMATA PHARMACEUTICALS, INC. |
| 07/11/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/07/2023 |
4
| DENNER ALEXANDER J (10% Owner) has filed a Form 4 on Innoviva, Inc.|
Txns:
| Bought 7,000 shares
@ $13.0424, valued at
$91.3k
Bought 8,000 shares
@ $13.048, valued at
$104.4k
|
|
| 05/30/2023 |
4
| DENNER ALEXANDER J (10% Owner) has filed a Form 4 on Innoviva, Inc.|
Txns:
| Bought 50,000 shares
@ $13.0866, valued at
$654.3k
Bought 30,000 shares
@ $13.1243, valued at
$393.7k
Bought 120,000 shares
@ $13.0054, valued at
$1.6M
|
|
| 05/24/2023 |
4
| Srivastava Sapna (Director) has filed a Form 4 on Innoviva, Inc.|
Txns:
| Granted 16,495 shares
@ $0
Granted 10,000 options to buy
@ $13.64, valued at
$136.4k
|
|
| 05/24/2023 |
4
| Birx Deborah (Director) has filed a Form 4 on Innoviva, Inc.|
Txns:
| Granted 16,495 shares
@ $0
Granted 10,000 options to buy
@ $13.64, valued at
$136.4k
|
|
| 05/24/2023 |
4
| Schlesinger Sarah J. (Director) has filed a Form 4 on Innoviva, Inc.|
Txns:
| Granted 16,495 shares
@ $0
Granted 10,000 options to buy
@ $13.64, valued at
$136.4k
|
|
| 05/24/2023 |
4
| Haimovitz Jules (Director) has filed a Form 4 on Innoviva, Inc.|
Txns:
| Granted 16,495 shares
@ $0
Granted 10,000 options to buy
@ $13.64, valued at
$136.4k
|
|
| 05/24/2023 |
4
| DiPaolo Mark (Director) has filed a Form 4 on Innoviva, Inc.|
Txns:
| Granted 16,495 shares
@ $0
Granted 10,000 options to buy
@ $13.64, valued at
$136.4k
|
|
| 05/24/2023 |
4
| Odysseas Kostas D (Director) has filed a Form 4 on Innoviva, Inc.|
Txns:
| Granted 16,495 shares
@ $0
Granted 10,000 options to buy
@ $13.64, valued at
$136.4k
|
|
| 05/24/2023 |
8-K
| Investor presentation |
| 05/23/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/23/2023 |
4
| Zhen Marianne (Chief Accounting Officer) has filed a Form 4 on Innoviva, Inc.|
Txns:
| Granted 1,576 shares
@ $0
Paid exercise price by delivering 784 shares
@ $13.47, valued at
$10.6k
|
|
| 05/19/2023 |
4/A
| DENNER ALEXANDER J (10% Owner) has filed a Form 4 on Innoviva, Inc.|
Txns:
| Bought 50,000 shares
@ $13.0738, valued at
$653.7k
Bought 10,000 shares
@ $13.0538, valued at
$130.5k
Bought 36,000 shares
@ $13.4763, valued at
$485.1k
|
|
| 05/19/2023 |
4
| DENNER ALEXANDER J (10% Owner) has filed a Form 4 on Innoviva, Inc.|
Txns:
| Bought 50,000 shares
@ $13.0738, valued at
$653.7k
Bought 10,000 shares
@ $13.0538, valued at
$130.5k
|
|
| 05/17/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/15/2023 |
4
| DENNER ALEXANDER J (10% Owner) has filed a Form 4 on Innoviva, Inc.|
Txns:
| Bought 290,000 shares
@ $12.3359, valued at
$3.6M
|
|
| 05/15/2023 |
3
| DENNER ALEXANDER J (10% Owner) has filed a Form 3 on Innoviva, Inc. |
| 05/15/2023 |
SC 13D/A
| Sarissa Capital Management LP reports a 10.5% stake in Innoviva, Inc. |
| 05/09/2023 |
8-K
| Quarterly results |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/20/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 03/14/2023 |
4
| Raifeld Pavel (CEO) has filed a Form 4 on Innoviva, Inc.|
Txns:
| Bought 3,000 shares
@ $10.8677, valued at
$32.6k
|
|
| 02/28/2023 |
8-K
| Quarterly results |
| 02/22/2023 |
4
| Zhen Marianne (Chief Accounting Officer) has filed a Form 4 on Innoviva, Inc.|
Txns:
| Paid exercise price by delivering 1,852 shares
@ $12.42, valued at
$23k
|
|
|